Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Phase II trial of vorinostat in advanced melanoma.

Investigational new drugs - 1 Jun 2014

Haas N B, Quirt I, Hotte S, McWhirter E, Polintan R, Litwin S, Adams P D, McBryan T, Wang L, Martin L P, vonMehren M, Alpaugh R K, Zweibel J, Oza A

Abstract excerpt

INTRODUCTION: Vorinostat is a small molecule inhibitor of class I and II histone deacetylases with preclinical activity in melanoma. METHODS: We evaluated 32 patients with advanced primary cutaneous or ocular melanoma in a multi-institutional setting (PMH Phase II Consortium) with continuous daily oral vorinostat 400 mg. The primary endpoint was response rate by RECIST, with time to progression as a secondary...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Disease-Free Survival
Share to Fibroblast Growth Factors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Histone Deacetylase Inhibitors

Share to Histones

Share to Hydroxamic Acids

Share to Melanoma, Cutaneous Malignant

Share to Vascular Endothelial Growth Factor A

Share to Vorinostat

Source

Identifiers

PMID: 24464266
DOI: 10.1007/s10637-014-0066-9

Genes

BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 11 closest

Phase II trial of vorinostat in advanced melanoma.PMID 24464266Read ↗

Vorinostat in patients with resistant BRAFV600E mutated advanced melanoma: a proof of concept study.Semantic proximity Read ↗

Inhibition of histone deacetylases in melanoma—a perspective from bench to bedsideSemantic proximity Read ↗

Role of Histone Deacetylases in Drug-Resistant Melanoma: Mechanisms and Therapeutic ImplicationsSemantic proximity Read ↗

Major therapeutic developments and current challenges in advanced melanoma.Semantic proximity Read ↗

A Proof-of-Concept Study of Sequential Treatment with the HDAC Inhibitor Vorinostat following BRAF and MEK Inhibitors in BRAFV600-Mutated Melanoma.Semantic proximity Read ↗

Systemic Therapy Options for Patients With Unresectable Melanoma.Semantic proximity Read ↗

Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma.Semantic proximity Read ↗

Biomarker Analysis in a Phase II Study of Sunitinib in Patients with Advanced Melanoma.Semantic proximity Read ↗

Histone Deacetylase Inhibitors Induce Growth Arrest and Differentiation in Uveal MelanomaSemantic proximity Read ↗

Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers.Semantic proximity Read ↗

Expression of the class 1 histone deacetylases HDAC8 and 3 are associated with improved survival of patients with metastatic melanoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.